Literature DB >> 12732930

Transfection of normal primary human skeletal myoblasts with p21 and p57 antisense oligonucleotides to improve their proliferation: a first step towards an alternative molecular therapy approach of Duchenne muscular dystrophy.

Stefanie Endesfelder1, Sabine Bucher, Alexander Kliche, Regina Reszka, Astrid Speer.   

Abstract

Duchenne muscular dystrophy (DMD), caused by the absence of dystrophin, is associated with decreased muscle cell proliferation. An increased p21 mRNA level in DMD patients may be involved in the process. In this context we are interested to improve the proliferation of primary human skeletal muscle cells (SkMC) by a reduction in the cell cycle proteins p21 and p57 using the appropriate antisense oligonucleotides (ASO). Therefore a transfection procedure needs to be optimized in which the oligonucleotide enters the SkMC with a minimal loss of cell vitality and high efficiency. Three different formulations, Effectene, DAC40, and SuperFect, were compared. Proliferation was analyzed comparing cells transfected with p21 and/or p57 ASO vs. cells transfected with scrambled ASO using a bromodeoxyuridine assay. Under optimal conditions (a mixture of 0.25 microg ASO, 5 microl Effectene, 0.8 microl enhancer) SkMC transfected with p21 ASO reveal an average increase in cell proliferation of 32.5+/-11% after 24 h. p57 ASO shows the same effect, but concomitant transfection of p21 and p57 does not enhance it. A cell vitality of 78+/-14% after 24 h was determined by the MTT test. SkMC transfected with DAC40 reveal a maximal increase in proliferation of 38+/-7% after 48 h and show a vitality of 65+/-8%. In contrast to both these formulations, SuperFect was found to be highly toxic for SkMC, with more than 70% dead cells after 24 h. The increase in proliferation, the functional biological effect of p21 ASO, is well correlated with a decrease in p21 detected by western blot analysis of 31.6% for Effectene. Transfection efficiency was measured directly by FACS analysis using FITC-labeled ASO and data showing ASO internalization in 75.8+/-11.2% of the cell population for Effectene and 74.4+/-6.6% cells for DAC40. Taken together transient transfection of p21 or p57 ASO into primary human SkMC using Effectene significantly improves their proliferation compared to transfection with scrambled ASO without a major loss of cell vitality. This represents a basis for the transfer of this technique to dystrophin-deficient SkMC cultures and the introduction of the short interference-RNA technique which might enhance the effect on cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12732930     DOI: 10.1007/s00109-003-0439-6

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  24 in total

1.  In vivo targeted repair of a point mutation in the canine dystrophin gene by a chimeric RNA/DNA oligonucleotide.

Authors:  R J Bartlett; S Stockinger; M M Denis; W T Bartlett; L Inverardi; T T Le; N thi Man; G E Morris; D J Bogan; J Metcalf-Bogan; J N Kornegay
Journal:  Nat Biotechnol       Date:  2000-06       Impact factor: 54.908

2.  Astrocyte progression from G1 to S phase of the cell cycle depends upon multiple protein interaction.

Authors:  A Pedram; M Razandi; R M Hu; E R Levin
Journal:  J Biol Chem       Date:  1998-05-29       Impact factor: 5.157

3.  Gene expression comparison of biopsies from Duchenne muscular dystrophy (DMD) and normal skeletal muscle.

Authors:  Judith N Haslett; Despina Sanoudou; Alvin T Kho; Richard R Bennett; Steven A Greenberg; Isaac S Kohane; Alan H Beggs; Louis M Kunkel
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-01       Impact factor: 11.205

4.  Full functional rescue of a complete muscle (TA) in dystrophic hamsters by adeno-associated virus vector-directed gene therapy.

Authors:  X Xiao; J Li; Y P Tsao; D Dressman; E P Hoffman; J F Watchko
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

5.  Rescue of dystrophin expression in mdx mouse muscle by RNA/DNA oligonucleotides.

Authors:  T A Rando; M H Disatnik; L Z Zhou
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

6.  Antisense oligonucleotide of WAF1 gene prevents EGF-induced cell-cycle arrest in A431 cells.

Authors:  M Ohtsubo; S Gamou; N Shimizu
Journal:  Oncogene       Date:  1998-02-12       Impact factor: 9.867

7.  Elevated p21 mRNA level in skeletal muscle of DMD patients and mdx mice indicates either an exhausted satellite cell pool or a higher p21 expression in dystrophin-deficient cells per se.

Authors:  S Endesfelder; A Krahn; K A Kreuzer; U Lass; C A Schmidt; C Jahrmarkt; A von Moers; A Speer
Journal:  J Mol Med (Berl)       Date:  2000       Impact factor: 4.599

8.  Defective myoblasts identified in Duchenne muscular dystrophy.

Authors:  H M Blau; C Webster; G K Pavlath
Journal:  Proc Natl Acad Sci U S A       Date:  1983-08       Impact factor: 11.205

9.  Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse.

Authors:  C J Mann; K Honeyman; A J Cheng; T Ly; F Lloyd; S Fletcher; J E Morgan; T A Partridge; S D Wilton
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

10.  Analysis of differential lipofection efficiency in primary and established myoblasts.

Authors:  Francesca Pampinella; Delphine Lechardeur; Elena Zanetti; Ian MacLachlan; Mohammed Benharouga; Gergely L Lukacs; Libero Vitiello
Journal:  Mol Ther       Date:  2002-02       Impact factor: 11.454

View more
  3 in total

1.  Analysis of novel nonviral gene transfer systems for gene delivery to cells of the musculoskeletal system.

Authors:  Patrick Orth; Anja Weimer; Gunter Kaul; Dieter Kohn; Magali Cucchiarini; Henning Madry
Journal:  Mol Biotechnol       Date:  2007-10-17       Impact factor: 2.695

2.  Antisense oligonucleotides and short interfering RNAs silencing the cyclin-dependent kinase inhibitor p21 improve proliferation of Duchenne muscular dystrophy patients' primary skeletal myoblasts.

Authors:  Stefanie Endesfelder; Alexander Kliche; Hanns Lochmüller; Arpad von Moers; Astrid Speer
Journal:  J Mol Med (Berl)       Date:  2004-11-05       Impact factor: 4.599

3.  Sirt1 increases skeletal muscle precursor cell proliferation.

Authors:  Christopher R Rathbone; Frank W Booth; Simon J Lees
Journal:  Eur J Cell Biol       Date:  2008-10-14       Impact factor: 4.492

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.